Loading data for AGIO — first visit, this takes a few seconds.

アラート

Agios Pharmaceuticals Inc... (AGIO)

NasdaqGS: AGIO · リアルタイム株価 · USD

33.63

-1.49 (-4.24%)

終値時点： Aug 21, 2026, 8:00 PM

33.39

+0.92%

時間外: 5:41 PM

株価、主要な数字、最新ニュースをひとまとめにしたページです。

-4.24% (1D)

データがありません

買気配	24.95
時価総額	1.98B
売上高（TTM）	98.34M
純利益（TTM）	-411.29M
	0.59
	-7.01
	n/a
	-8.38
PBR（TTM）	1.92
PSR（TTM）	20.09
決算発表日	Oct 29, 2026

売気配	43.34
出来高	697,492
平均出来高（20日）	1,172,008
始値	34.64
前日終値	35.12
当日レンジ	33.61 - 35.09
52週レンジ	22.24 - 46.00
アナリスト	n/a
目標株価	n/a
配当	n/a
権利落ち日	n/a

AGIOについて

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical...

[続きを読む]

業種 Biotechnology

セクター Healthcare

IPO日 Jul 24, 2013

従業員数 539

上場取引所 NasdaqGS

ティッカー AGIO

ウェブサイト https://www.agios.com

企業情報の全文

業績

2025年のAgios Pharmaceuticalsの売上高は54.03Mで、前年の36.5Mから48.03%の増加でした。利益は-412.78Mで、-161.27%の減少でした。

財務諸表

決算サプライズ

Agios PharmaceuticalsはJul 30, 2026に四半期決算を発表しました：

売上高は $44.74M で、予想を下回りました $0, うち 259.25% の前年比増加にあたります.
EPSは -1.69 で、予想を下回りました -0.03, うち 12.44% の前年比増加にあたります.

次回決算発表

Agios Pharmaceuticals Inc.の決算発表予定日は Oct 29, 2026, 寄り付き前の予定です。
アナリストの売上高予想は ... アップグレード

ニュース

3週間前 · Zacks

AGIO Q2 Earnings Beat Estimates, Revenues Increase Year Over Year

Agios tops Q2 revenue and earnings estimates as Aqvesme's launch and Pyrukynd sales fuel growth, while advancing its hematology pipeline.

3週間前 · GuruFocus.com

Agios Pharmaceuticals Inc (AGIO) (Q2 2026) Earnings Call Highlights: Strong Mitapivat Revenue ...

Agios reports $44.7 million in Q2 mitapivat revenue and FDA priority review for sickle cell disease, while advancing pipeline diversification with cevidoplenib.

3週間前 · MarketBeat

Agios Pharmaceuticals Q2 Earnings Call Highlights

Agios Pharmaceuticals (NASDAQ:AGIO) reported second-quarter 2026 mitapivat net revenue of $44.7 million, including $40.9 million in the United States and $3.8 million outside the U.S., as the company ...

3週間前 · Zacks

Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimates

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of +9.14% and +97.29%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

3週間前 · Simply Wall St.

Tebapivat Sickle Cell Setback and Mitapivat Priority Review Could Be A Game Changer For Agios (AGIO)

In July 2026, Agios Pharmaceuticals reported topline Phase 2 results for tebapivat in sickle cell disease, showing hemoglobin and hemolysis improvements but insufficient differentiation versus placebo...

2ページ中1ページ

Agios Pharmaceuticals Inc... (AGIO)